INS and diabetes mellitus: Mifepristone, a glucocorticoid and progesterone receptor antagonist, has been shown to improve insulin sensitivity and decrease fasting plasma glucose concentrations and HbA1c concentrations in patients with Cushing’s disease and impaired glucose tolerance or diabetes mellitus (27).